Acadia Pharmaceuticals reported a strong first quarter for 2026, with total revenues of $268 million, reflecting an 11% year-over-year increase. Notably, DAYBUE achieved net sales of $101 million, marking a 20% growth and the highest annual rate since 2024, driven by the successful launch of DAYBUE STIX. Meanwhile, NUPLAZID generated $167 million in sales, up 6% year-over-year, bolstered by an 11% rise in physician referrals, despite earlier delays in patient prescription refills.
These results underscore Acadia’s robust market position and growth potential, particularly with the anticipated Phase II readout for remifanserin in Alzheimer’s disease psychosis expected between August and October. The company maintains its financial guidance for 2026, projecting total revenues of $1.22 billion to $1.28 billion, while also highlighting a strong cash position of $851 million, which supports ongoing R&D and commercial initiatives.
For investors, Acadia’s reaffirmed guidance and upcoming clinical milestones present significant opportunities for growth, particularly as new product formulations and international programs expand its market reach.
Source: fool.com